Lactasin (Biofermin) Veterinary Grade API is a lyophilized live lactic acid bacterial preparation supplied as an off-white to tan powder for incorporation into tablets, capsules, oral powders, granules, drinking-water solutions, feed premixes, and, where indicated, sterile cell-free derivatives for injection. The material is standardized on viable count rather than inert dry weight because the therapeutic effect depends on the number of colony-forming units that survive upstream processing, storage, and the target animal’s gastrointestinal transit. Manufacturing comprises controlled submerged fermentation of selected lactic acid bacteria, centrifugal concentration, cryoprotectant addition, lyophilization under low-humidity conditions, and low-shear milling. The Biofermin designation refers to the marketed probiotic complex, while Lactasin is the nonproprietary veterinary API name. Two common supply modes are available: a concentrated lyophilized API powder standardized to ≥1.0 × 10^10 CFU/g for tablets, capsules, and oral solutions, and a microencapsulated premix-grade granule with lower viable count but greater resistance to feed-pelleting temperatures. The API is packaged in sealed aluminium-foil laminate bags with desiccant under nitrogen headspace to maintain water activity below 0.20; exposure to ambient relative humidity above 35% RH during dispensing is limited to less than 30 min to avoid moisture uptake and premature loss of viability.

Which release tests and specification bands control the veterinary API?

The API is released against a matrix of microbiological, physicochemical, and identity tests. Because national and regional pharmacopoeias do not contain a fully harmonized monograph for every Lactasin strain combination, release testing commonly aligns with the general chapters for nonsterile microbial enumeration and feed-additive contaminants. Table 1 lists representative release bands used during supplier qualification and site transfer; exact product-specific limits appear on the manufacturer’s certificate of analysis and must be reconfirmed for each batch. The primary strength parameter is viable count determined by pour-plate enumeration on MRS agar, because cell count, not dry mass, defines the effective dose.

Compression, capsule filling, and premix homogeneity constraints

Direct compression of Lactasin-containing tablets is preferred over wet granulation because aqueous granulation and high-shear mixing can reduce viable count by more than 1.0 log₁₀ when unprotected cells are exposed to moisture. On rotary tablet presses, formulations are designed to keep compression force between 8 kN and 15 kN for 10 mm standard concave tooling, with tablet hardness between 50 N and 80 N. Higher compaction pressures reduce disintegration time and may damage lyophilized cells; lower pressures produce friable tablets outside USP <1216> limits. A typical direct-compression matrix uses microcrystalline cellulose, crospovidone, sodium starch glycolate, and magnesium stearate. Lactose monohydrate is generally avoided in formulations where lactose-intolerant target animals or label restrictions apply.

Capsule filling on dosator-nozzle or tamping-pin machines requires granulated material with bulk density between 0.45 g/mL and 0.65 g/mL and Carr compressibility below 20%. Poor flow increases fill-weight variability and can segregate the API from glidants; colloidal silicon dioxide at 0.5–1.0% w/w is used to reduce interparticle cohesion. Low-humidity encapsulation suites are maintained at 20–25 °C and ≤30% RH; capsule shells should have moisture content below 12% to avoid embrittlement or sticking. For powder and granule blends intended for drinking-water solutions, the API is diluted geometrically into dextrose monohydrate, sodium chloride, citric acid, or buffered electrolyte bases. The final container should deliver a uniformly dispersed suspension; sedimentation of live cells is minimized by using a particle size distribution with 90% of particles passing through a 180 μm sieve. Premix homogeneity is evaluated by replicated viable count assays at the top, middle, and bottom of the blender, with a target coefficient of variation not exceeding 5%.

If wet granulation is unavoidable for a sustained-release or taste-masked oral powder, low-shear fluid-bed top-spray granulation is used. An aqueous binder solution containing 5% w/w polyvinylpyrrolidone K30 is sprayed at product temperature 28–32 °C, with inlet air dew point below −10 °C; the process is stopped when granule moisture reaches 3–5%. Development batches typically maintain viable count loss below 0.5 log₁₀ under this regime; published data for all strain variants are limited.

Where the product listing includes an injection-grade presentation, the live whole-cell Lactasin API is not appropriate for parenteral administration. Intramuscular, subcutaneous, or intravenous injection of viable lactic acid bacteria can produce injection-site abscesses, bacteraemia, and systemic inflammatory responses. For injectable veterinary products, the API must be a depyrogenated, sterile-filtered cell-free supernatant or a purified intracellular fraction. This material is clarified through 0.45 μm and 0.22 μm polyethersulfone membrane filters, then filled under aseptic conditions. Bacterial endotoxin is controlled by the limulus amebocyte lysate method described in USP <85>; a typical parenteral acceptance limit is ≤0.5 EU/mL for small-volume aqueous injections. Whole-cell live powder should never be sterilized by moist heat or gamma irradiation because both treatments destroy the stated viable count. Published data for injectable whole-cell Lactasin are limited because such use is outside the product’s intended oral route.

When heat stress during feed pelleting overrides viable count retention

Feed premix and pellet applications impose a different thermal stress profile than oral powders. Standard steam-conditioned pelleting at 70–85 °C can reduce unprotected Lactasin viable count by 1–3 log₁₀ during a residence time of 10–30 s; post-pelleting recovery is therefore inadequate unless the API is microencapsulated or applied after the pellet cooling stage. For heat-sensitive Lactasin, post-pelleting liquid or vacuum coating onto cooled pellets at product temperature below 40 °C is the preferred route. Microencapsulation matrices based on hydrogenated vegetable oil, calcium alginate, or whey protein isolate are used to shift survival; the coating should survive 30 min in simulated gastric fluid at 39 °C and release viable cells in simulated intestinal fluid within 45 min. In extruded feeds, barrel temperature at the die should not exceed 50–60 °C if the API is incorporated pre-extrusion; otherwise the viable count specification at the finished feed level cannot be guaranteed.

Differences from feed-grade probiotic premixes are not limited to viable count. Veterinary API-grade Lactasin is manufactured under dedicated fermentation and lyophilization lines with segregation of bacterial cultures, controlled mycoplasma screening, and stability data generated under VICH conditions. Feed-grade material may carry higher non-lactic bioburden, less stringent pathogen testing, and wider moisture or carrier variability. The API is supplied without a full premix carrier system, allowing the formulator to control the final inactive matrix; feed-grade products often contain limestone, rice hulls, or wheat middlings that can interfere with tablet binding or capsule flow. Table 2 summarises the principal differences across common product classes.

Regulatory alignment also differs. In the European Union, feed probiotic preparations fall under Regulation (EC) No 1831/2003 as zootechnical additives, whereas veterinary dosage forms prepared from this API are governed by national veterinary medicinal product requirements and good manufacturing practice for active substances. In the United States, direct-fed microbial products may be listed with the AAFCO Official Publication, while the finished dosage form may require an approved or conditionally approved new animal drug application depending on label claims. These distinctions affect labelling, stability documentation, and residue compliance.

Long-term stability of Lactasin API is strongly dependent on water activity and oxygen exclusion. The product is typically packed in multi-layer aluminium-foil bags under nitrogen with residual oxygen headspace below 2% v/v. Storage at 2–8 °C is recommended for pharmaceutical intermediates intended for oral dosage forms; ambient storage at 25 °C / 60% RH is acceptable only if water activity remains ≤0.20 and desiccant is present. Stability projections for similar lactic acid bacterial powders show a loss rate of 0.02–0.05 log₁₀ CFU/g per month at refrigerated temperature; at 30 °C the rate can increase to 0.2–0.5 log₁₀ CFU/g per month depending on strain and cryoprotectant. These rates justify an overage of 0.3–0.5 log₁₀ at release if ambient distribution is intended. The product should not be co-stored with hygroscopic salts, acids, or volatile organic solvents because moisture and acid vapours accelerate viability loss.

For oral solutions, the API is reconstituted immediately before use. Lactasin whole-cell suspensions in drinking water are stable for no more than 4–6 h at 25 °C and 12 h at 2–8 °C; after this period, viable count and sedimentation become unpredictable. The formulated solution should be buffered to pH 6.0–7.0 and should not be combined with chlorinated water or disinfectants because free chlorine at 0.5 mg/L can inactivate lactic acid bacteria within minutes.